These findings underscore the importance of assessing SUCLA2 variants in patients with severe early progressive encephalomyopathy, even in the absence of methylmalonic aciduria or mtDNA loss, thereby broaden the mutational spectrum of this gene. Here, SUCLA2 is linked to mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria.